2023
DOI: 10.1016/j.bbcan.2023.188887
|View full text |Cite
|
Sign up to set email alerts
|

Cancer stem cell in prostate cancer progression, metastasis and therapy resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 337 publications
1
5
0
Order By: Relevance
“…CD133, CD44, KLF4, SOX2, ALDH1A1, and other proteins have been regarded as the hallmarks for PCSCs [ 19 ]. In the present study, we chose CD133, CD44, KLF4, SOX2, and ALDH to assess the stemness of PCSCs.…”
Section: Resultsmentioning
confidence: 99%
“…CD133, CD44, KLF4, SOX2, ALDH1A1, and other proteins have been regarded as the hallmarks for PCSCs [ 19 ]. In the present study, we chose CD133, CD44, KLF4, SOX2, and ALDH to assess the stemness of PCSCs.…”
Section: Resultsmentioning
confidence: 99%
“…Whether this phenomenon can be attributed to the characteristics of cancer stem cells, making them more resistant to the cytotoxicity of Cl80, requires further investigation. It is noteworthy that numerous studies have highlighted the inherent resistance of cancer stem cells to anticancer drugs [38].…”
Section: Discussionmentioning
confidence: 99%
“…CSCs play a critical role in cancer progression and recurrence and, thus, have potential as a therapeutic target for cancer therapy [ 43 ]. The present study is the first to support the notion that K + channel inhibition-mediated intracellular signaling may reduce cancer stemness by transcriptionally up-regulating the E3 ubiquitin ligase, FBXW7, in cancer spheroids with CSC properties.…”
Section: Discussionmentioning
confidence: 99%